Durata Therapeutics, Inc. Names Wendy Yarno And J. Martin Carroll To Its Board Of Directors

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Wendy Yarno and Marty Carroll were added to its Board of Directors at a quarterly meeting of the Board held today. The Company also announced the departure of Mr. Ronald Hunt from its Board, also effective as of this meeting. Ms. Yarno and Mr. Carroll fill an existing vacancy and the position vacated by Mr. Hunt, respectively.

"We are very pleased to welcome Ms. Yarno and Mr. Carroll to our Board of Directors. Both are seasoned executives with extensive leadership experience at large pharmaceutical companies," said Richard De Schutter, Durata's Chairman of the Board. "We would also like to thank Ron for his many contributions and his commitment to Durata."

Ms. Yarno held positions of increasing responsibility and was responsible for leading multiple business groups during her 26-year career at Merck & Co, Inc. Most recently, she served as Executive Vice President and Chief Marketing Officer where she led the global organization of more than 3,000 individuals responsible for supporting product commercialization across more than 20 therapeutic areas. Ms. Yarno also served as Merck's Senior Vice President of Human Resources, where her successful efforts to develop and implement new corporate personnel strategies proved transformative for this key business function. Ms. Yarno was also Vice President of Johnson & Johnson, Ortho McNeil Pharmaceutical's highly profitable Women's Health Care Franchise. Ms. Yarno received an M.B.A. from the Fox School of Business at Temple University and a B.S. in business administration from Portland State University. She also serves on the Board of Directors for St. Jude Medical, Medivation, and Aratana Therapeutics.

Mr. Carroll served as President and Chief Executive Officer of Boehringer Ingelheim Corporation (US) from 2003 until 2011. He also served as Global Head of Corporate Strategy and Development for Boehringer Ingelheim (Germany) from 2009 through 2012. In addition, Mr. Carroll served as Chairman of the Board for a number of Boehringer Ingelheim companies in the US from 2002 to 2012. Previously, Mr. Carroll held positions of increasing responsibility with Merck & Co., Inc. from 1976 to 2001 including Manufacturing, International (Japan), and Marketing and Sales. At the time he left Merck, he was serving as its Executive Vice President, Customer Marketing and Sales of Merck's US Human Health Division. From 1972 to 1976, Mr. Carroll served in the United States Air Force. Mr. Carroll has previously served on the Board of Directors for Accredo Health, Gwynedd Mercy College, as well as PhRMA. He currently serves as a director of Mallinckrodt Plc. Mr. Carroll received a B.A. in accounting and economics from the College of the Holy Cross and a M.B.A. from Babson College.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

Forward-looking Statements

Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.

CONTACT: Allison Wey Durata Therapeutics, Inc. Vice President, Investor Relations and Public Affairs (312) 219-7017 awey@duratatherapeutics.com

Durata Therapeutics, Inc. Logo

Help employers find you! Check out all the jobs and post your resume.

Back to news